Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting
Authors:
- Camille LenoirCLCamille Lenoir
- Jean TerrierJTJean Terrier
- Yvonne GloorYGYvonne Gloor
- Pauline GosselinPGPauline Gosselin
- Youssef DaaliYoussef Daali
- Christophe CombescureCCChristophe Combescure
- Jules Alexandre DesmeulesJules Alexandre Desmeules
- Caroline Flora SamerCSCaroline Flora Samer
- Jean-Luc RenyJRJean-Luc Reny
- Victoria RollasonVRVictoria Rollason
Open Access
- 24 March 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (4) , 526
Abstract
Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the increased use of DOACs in real-world settings, safety and efficacy concerns have emerged, particularly regarding their concomitant use with other drugs. Increasing evidence highlights drug–drug interactions with CYP3A/P-gp modulators leading to adverse events. However, current recommendations for dose adjustment do not consider CYP3A/P-gp genotype and phenotype. We aimed to determine their impact on apixaban and rivaroxaban blood exposure. Three-hundred hospitalized patients were included. CYP3A and P-gp phenotypic activities were assessed by the metabolic ratio of midazolam and AUC0–6h of fexofenadine, respectively. Relevant CYP3A and ABCB1 genetic polymorphisms were also tested. Capillary blood samples collected at four time-points after apixaban or rivaroxaban administration allowed the calculation of pharmacokinetic parameters. According to the developed multivariable linear regression models, P-gp activity (p < 0.001) and creatinine clearance (CrCl) (p = 0.01) significantly affected apixaban AUC0–6h. P-gp activity (p < 0.001) also significantly impacted rivaroxaban AUC0–6h. The phenotypic switch (from normal to poor metabolizer) of P-gp led to an increase of apixaban and rivaroxaban AUC0–6h by 16% and 25%, respectively, equivalent to a decrease of 38 mL/min in CrCl according to the apixaban model. CYP3A phenotype and tested SNPs of CYP3A/P-gp had no significant impact. In conclusion, P-gp phenotypic activity, rather than known CYP3A/P-gp polymorphisms, could be relevant for dose adjustment.Keywords
Funding Information
- Hôpitaux Universitaires de Genève (19-2014-II)
This publication has 93 references indexed in Scilit:
- Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Applications of CYP450 Testing in the Clinical SettingMolecular Diagnosis & Therapy, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Pharmacokinetics in special populationsDrug Metabolism Reviews, 2009
- Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human HepatocytesDrug Metabolism and Disposition, 2007
- REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATIONAnnual Review of Pharmacology and Toxicology, 2006
- Drug Metabolism and Variability among Patients in Drug ResponseNew England Journal of Medicine, 2005
- A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routesJournal of Pharmaceutical and Biomedical Analysis, 2004
- Role of P-Glycoprotein in PharmacokineticsClinical Pharmacokinetics, 2003
- Cytokine Regulation of P-GlycoproteinDrug Metabolism Reviews, 2003